Kevin DeGeeter

Stock Analyst at Ladenburg Thalmann

(2.86)
# 1,629
Out of 5,043 analysts
45
Total ratings
38.24%
Success rate
55.18%
Average return

Stocks Rated by Kevin DeGeeter

ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $13.40
Upside: +11.94%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.29
Upside: +729.69%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $13.58
Upside: +120.91%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.35
Upside: +1,529.63%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30$24
Current: $9.68
Upside: +147.93%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141$125
Current: $23.31
Upside: +436.25%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $4.79
Upside: +275.78%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.74
Upside: +408.02%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.29
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75$79
Current: $220.29
Upside: -64.06%
Maintains: Outperform
Price Target: $161$155
Current: $63.50
Upside: +144.09%
Downgrades: Perform
Price Target: n/a
Current: $10.12
Upside: -
Initiates: Outperform
Price Target: $25
Current: $9.45
Upside: +164.55%
Initiates: Outperform
Price Target: $1,800
Current: $6.13
Upside: +29,263.78%
Downgrades: Perform
Price Target: n/a
Current: $36.48
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $4.88
Upside: -
Downgrades: Perform
Price Target: n/a
Current: $3.94
Upside: -
Initiates: Outperform
Price Target: $1,500
Current: $3.59
Upside: +41,682.73%
Initiates: Outperform
Price Target: $900
Current: $1.91
Upside: +47,020.42%
Upgrades: Buy
Price Target: n/a
Current: $8.70
Upside: -
Initiates: Buy
Price Target: $165
Current: $12.98
Upside: +1,171.19%
Initiates: Buy
Price Target: $225
Current: $99.98
Upside: +125.05%
Upgrades: Neutral
Price Target: n/a
Current: $8.10
Upside: -
Upgrades: Buy
Price Target: n/a
Current: $2.60
Upside: -